PTE News and Press, PolarityTE Inc. From 11/09/20

PolarityTE (PTE): Q3 GAAP EPS of -$0.18 beats by $0.02.Revenue of $3.34M (+138.6% Y/Y) beats by $0.37M.Press Release For further details see: PolarityTE EPS beats by $0.02, beats on revenue

PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the third calendar quarter of 2020. PolarityTE will host a conference call and webcast today, November 9, 2020 at 8:00 a.m. ET. ...

PolarityTE Plans to Submit an Investigational New Drug (IND) Submission for One or More Indications in the Second Half of 2021 PolarityTE, Inc. (Nasdaq: PTE) announced that it recently received written responses from FDA following a Type B Pre-IND meeting request that th...

Catabasis Pharmaceuticals (CATB) -64% after halting development of edasalonexent.Dragon Victory International (LYL) -17%.Sharps Compliance (SMED) -11% on FQ1 earning release.Liquid Media Group (YVR) -7%.BiondVax Pharmaceuticals (BVXV) -6%.Muscle Maker (GRIL) -6%.Teck ...

PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar third quarter 2020 financial results by press release on Monday, November 9, 2020 at approximately 7:00 a.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on...

PolarityTE (PTE) terminates the shareholder rights plan after receiving stockholder input and evaluating that input in the context of Company objectives.The termination of the shareholder rights plan, often referred to as a “poison pill,” is effective September 28, 2020.Source: ...

PolarityTE, Inc. (Nasdaq: PTE) today announced that the Board of Directors voted to terminate the Company’s shareholder rights plan after receiving stockholder input and evaluating that input in the context of Company objectives. The termination of the shareholder rights plan...

PolarityTE (PTE) rises 5.5% in premarket, after being awarded a Phase I Small Business Innovation Research grant from the National Institutes of Health ((NIH)) for point-of-care devices to treat chronic wounds.”The Phase I grant of ~$245k, is funded over a six-month peri...

PolarityTE, Inc. (Nasdaq: PTE) today announced it has received notification of being awarded a Phase I Small Business Innovation Research grant from the National Institutes of Health (NIH) for an application titled, “Fluid Management System for Point of Care Device for Novel ...

Shares of Co-Diagnostics (NASDAQ: CODX) have bounced around a bit this year, to say the least. At the start of the year, you could buy a share in the Salt Lake City-based molecular diagnostics company for less than a dollar. By Aug. 8, the price was $30.80 after the company announced it was...